# US 2025/0152094 A1 · System and method for monitoring an efficacy of a treatment for a cardiac condition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152094 A1
- Document ID: US20250152094A1
- Status: Published application
- Kind: A1
- Application number: 18/726,328
- Filed: 2023-01-04
- Published: 2025-05-15
- Earliest claimed: 2022-01-05
- Assignees: Prolaio, Inc.
- Applicants: Prolaio, Inc.
- Inventors: Jay M. Edelberg; Tassos Gianakakos
- Web page: https://patentgrep.com/patent/US20250152094A1

## CPC

- A61B 5/0035: {adapted for acquisition of images from more than one imaging mode, e.g. combining MRI and optical tomography}
- A61B 5/7267: {involving training the classification device}
- A61B 5/02007: {Evaluating blood vessel condition, e.g. elasticity, compliance}
- A61B 5/02028: {Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction}
- A61B 5/0205: Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
- A61B 5/024: Measuring pulse rate or heart rate
- A61B 5/026: Measuring blood flow {(A61B3/1233, A61B3/1241 take precedence)}
- A61B 5/029: Measuring blood output from the heart, e.g. minute volume
- A61B 5/1073: {Measuring volume, e.g. of limbs}
- A61B 5/1075: {for measuring dimensions by non-invasive methods, e.g. for determining thickness of tissue layer (A61B8/0858 takes precedence)}
- A61B 5/1076: {for measuring dimensions inside body cavities, e.g. using catheters (A61B3/1005 takes precedence)}
- A61B 5/1107: {Measuring contraction of parts of the body, e.g. organ or muscle}
- A61B 5/1118: {Determining activity level}
- A61B 5/256: Wearable electrodes, e.g. having straps or bands
- A61B 5/282: Holders for multiple electrodes (for introduction into the body A61B5/287)
- A61B 5/332: Portable devices specially adapted therefor
- A61B 5/339: Displays specially adapted therefor
- A61B 5/346: Analysis of electrocardiograms
- A61B 5/353: Detecting P-waves
- A61B 5/355: Detecting T-waves
- A61B 5/358: Detecting ST segments
- A61B 5/361: Detecting fibrillation
- A61B 5/363: Detecting tachycardia or bradycardia
- A61B 5/366: Detecting abnormal QRS complex, e.g. widening
- A61B 5/4806: {Sleep evaluation (A61B5/4821 takes precedence; devices for inducing sleep A61M21/02)}
- A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication}
- A61B 5/7264: {Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems}
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- A61B 5/743: {Displaying an image simultaneously with additional graphical information, e.g. symbols, charts, function plots}
- A61B 5/7435: {Displaying user selection data, e.g. icons in a graphical user interface}
- A61B 5/746: {Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms}
- A61B 8/02: Measuring pulse or heart rate
- A61B 8/04: Measuring blood pressure
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H 15/00: ICT specially adapted for medical reports, e.g. generation or transmission thereof
- G16H 20/00: ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H 40/67: for remote operation
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 80/00: ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
- A61B 5/0044: {for the heart}
- A61B 5/055: involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
- A61B 8/0883: {for diagnosis of the heart}
- A61B 2576/023: for the heart
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Disclosed herein, in some aspects, are systems and methods for monitoring an efficacy of a treatment for a cardiac condition. In some embodiments, the systems and methods include a) obtaining a first set of subject health parameters of the subject that include a first set of ambulatory monitoring parameters; b) determining a first cardiac health status by applying one or more decision engines with one or more ambulatory monitoring parameters to determine a severity of a cardiac condition in the subject, and/or a risk score for developing the cardiac condition by the subject; c) detecting a cardiac health status change (CHS) in the severity and/or risk score based on a previous CHS; and d) identifying the efficacy of the treatment based on the detected CHS change.

## Claims

### Claim 1

A method for monitoring an efficacy of a treatment for a cardiac condition, the method comprising:
a. obtaining a first set of subject health parameters of the subject, wherein the first set of subject health parameters comprises a first set of ambulatory monitoring parameters;
b. determining a first cardiac health status by applying one or more decision engines with one or more ambulatory monitoring parameters of the first set of ambulatory monitoring parameters to determine i) a severity of a cardiac condition in the subject, and/or ii) a risk score for developing the cardiac condition by the subject;
c. detecting a cardiac health status (CHS) change in the severity and/or risk score based on a previous cardiac health status (CHS); and
d. identifying the efficacy of the treatment based on the detected CHS change, wherein i) an increase in the severity and/or an increase in the risk score correlates with a low efficacy treatment, and ii) a decrease in the severity and/or an decrease in the risk score correlates with a high efficacy treatment.

### Claim 2 (depends on 1)

The method of claim 1, further comprising prescribing i) a treatment change to the treatment, and/or ii) a new treatment based on identifying low efficacy treatment.

### Claim 3 (depends on 2)

The method of claim 2, wherein prescribing the new treatment comprises identifying the new treatment based on the cardiac health status and the first subject health parameters.

### Claim 4 (depends on 1)

The method of claim 1, further comprising outputting an alert based on identifying low efficacy treatment.

### Claim 5 (depends on 1)

The method of claim 1, further comprising repeating steps (a) to (d) a plurality of times for a prescribed duration, thereby providing monitoring of the efficacy of the treatment for the prescribed duration.

### Claim 6 (depends on 5)

The method of claim 5, wherein steps (a) to (d) are repeated according to a temporal frequency during the prescribed duration.

### Claim 7 (depends on 6)

The method of claim 6, wherein the temporal frequency is every hour, every 6 hours, every 12 hours, daily, every other day, weekly, bi-weekly, monthly, or bi-monthly.

### Claim 8 (depends on 1)

The method of claim 1, wherein the first set of ambulatory monitoring parameters comprises electrocardiogram (ECG) data and/or one or more clinical parameters.

### Claim 9 (depends on 8)

The method of claim 8, wherein the one or more clinical parameters comprises, the subject's age, sex, weight, body mass index, height, physiological data, exercise testing results, heart rate, activity levels, velocity, sleep data, or a combination thereof.

### Claim 10 (depends on 8)

The method of claim 8, wherein the ECG data is obtained via ECG device, wherein the ECG device comprises a 12-lead device, a 6-lead device, a 1-lead device, or a 2-lead device.

### Claim 11 (depends on 10)

The method of claim 10, wherein the ECG device comprises a wearable device.

### Claim 12 (depends on 1)

The method of claim 1, wherein the first set of subject health parameters further comprises one or more clinical biomarker data, and/or one or more imaging data.

### Claim 13 (depends on 12)

The method of claim 12, wherein the one or more clinical biomarker data comprise data for one or more of B-type natriuretic peptide (BNP), N-terminal (NT)-pro hormone BNP (NT-proBNP), and cardiac troponin.

### Claim 14 (depends on 12)

The method of claim 12, wherein the one or more imaging data comprises one or both of an echocardiogram image and a cardiac MRI.

### Claim 15 (depends on 1)

The method of claim 1, wherein the cardiac condition comprises a cardiac disease.

### Claim 16 (depends on 1)

The method of claim 1, wherein the cardiac condition comprises cardiomyopathy, hypertrophic cardiomyopathy, pulmonary arterial hypertension, amyloid cardiomyopathy, reduced ejection fraction heart failure, arrhythmia (which can include atrial fibrillation), heart failure, heart attack, stroke, myocardial ischemia (including macrovascular and/or microvascular), left atrial enlargement (LAE), left atrial myopathy, diastolic dysfunction, or any combination thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein the one or more decision engines comprise a trained model, a decision tree, an analytical expression, or a combination thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein the treatment comprises reducing ventricular filling pressures.

### Claim at position 19

19-36. (canceled)

### Claim 37

A system for monitoring an efficacy of a treatment for a cardiac condition, the system comprising:
one or more processors; and
one or more memories storing instructions that, when executed by the one or more processors, cause the system to perform operations including:
a. obtaining a first set of subject health parameters of the subject, wherein the first set of subject health parameters comprises a first set of ambulatory monitoring parameters;
b. determining a first cardiac health status by applying one or more decision engines with one or more ambulatory monitoring parameters of the first set of ambulatory monitoring parameters to determine i) a severity of a cardiac condition in the subject, and/or ii) a risk score for developing the cardiac condition by the subject;
c. detecting a cardiac health status (CHS) change in the severity and/or risk score based on a previous cardiac health status (CHS); and
d. identifying the efficacy of the treatment based on the detected CHS change, wherein i) an increase in the severity and/or an increase in the risk score correlates with a low efficacy treatment, and ii) a decrease in the severity and/or an decrease in the risk score correlates with a high efficacy treatment.

### Claim 38 (depends on 37)

The system of claim 37, wherein the operations further include prescribing i) a treatment change to the treatment, and/or ii) a new treatment based on identifying low efficacy treatment.

### Claim 39 (depends on 38)

The system of claim 38, wherein prescribing the new treatment comprises identifying the new treatment based on the cardiac health status and the first subject health parameters.

### Claim 40 (depends on 37)

The system of claim 37, wherein the operations further include outputting an alert based on identifying low efficacy treatment.

### Claim 41 (depends on 37)

The system of claim 37, wherein the operations further include repeating steps (a) to (d) a plurality of times for a prescribed duration, thereby providing monitoring of the efficacy of the treatment for the prescribed duration.

### Claim at position 25

42-43. (canceled)

### Claim 44 (depends on 37)

The system of claim 37, wherein the first set of ambulatory monitoring parameters comprises electrocardiogram (ECG) data and/or one or more clinical parameters.

### Claim at position 27

45-47. (canceled)

### Claim 48 (depends on 37)

The system of claim 37, wherein the first set of subject health parameters further comprises one or more clinical biomarker data, and/or one or more imaging data.

### Claim 49 (depends on 48)

The system of claim 48, wherein the one or more clinical biomarker data comprise data for one or more of B-type natriuretic peptide (BNP), N-terminal (NT)-pro hormone BNP (NT-proBNP), and cardiac troponin.

### Claim 50

(canceled)

### Claim 51 (depends on 37)

The system of claim 37, wherein the cardiac condition comprises a cardiac disease.

### Claim 52

(canceled)

### Claim 53 (depends on 37)

The system of claim 37, wherein the one or more decision engines comprise a trained model, a decision tree, an analytical expression, or a combination thereof.

### Claim 54 (depends on 37)

The system of claim 37, wherein the treatment comprises reducing ventricular filling pressures.
